Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ascendis Pharma reports strong revenue growth and market potential

Ascendis Pharma's financial performance in Q4 2022 showed revenue growth but operating losses, with a strong cash position.
Strengths lie in the TransCon technology platform, differentiation of products, and established commercial infrastructure.
Challenges include monitoring requirements, launch strategy comparisons, and market access strategies.
Opportunities arise from potential approvals, market dynamics, and clinical benefits of product candidates.

Ascendis Pharma reports robust Q1 revenue, faces regulatory challenges

Ascendis Pharma delivered a strong financial performance in Q1 2023, driven by revenue growth and strategic initiatives.
The company faces regulatory challenges and market dynamics that require resolution and strategic planning for sustained growth.
Opportunities for market expansion and product development exist through leveraging success factors and addressing regulatory hurdles.
Investor interest in Ascendis Pharma's future prospects is evident through analyst inquiries on growth expectations and market strategies.

Ascendis Pharma reports robust Q2 earnings amidst market challenges

Ascendis Pharma's Q2 performance reflects strong revenue generation and strategic advancements in key product pipelines, positioning the company for future growth.
Despite challenges in market shortages and regulatory processes, Ascendis Pharma's focus on innovation and market differentiation presents opportunities for expansion.
The company's emphasis on TransCon technology's unique benefits and market positioning underscores its competitive strength and growth potential in rare disease therapeutics.

Ascendis Pharma reports strong Q3 revenue growth and pipeline progress

Ascendis Pharma's Q3 2023 performance reflects revenue growth driven by SKYTROFA and progress in key pipeline programs.
The company's strategic focus on innovative therapies and patient-centric approaches positions it for future growth and market leadership.
While facing challenges like supply chain disruptions and market competition, Ascendis Pharma has opportunities for expansion and therapeutic innovation.
Balancing financial performance with pipeline advancement and commercial optimization will be crucial for Ascendis Pharma's sustainable success.

Ascendis Pharma excels in revenue growth and market leadership

Ascendis Pharma's strong performance in 2023, driven by SKYTROFA and TransCon PTH, positions the company for continued growth and success.
Despite challenges in market competition and treatment complexities, the company's strategic focus on patient outcomes and revenue growth is evident.
Opportunities in expanding therapeutic areas and maintaining market share stability offer potential for Ascendis Pharma's long-term success and value creation.

Ascendis Pharma reports robust Q1 performance and eyes global expansion

Ascendis Pharma's Q1 2024 performance reflects strong revenue growth, improved operational efficiency, and successful product launches, positioning the company for sustainable growth.
While facing challenges in market competition and financial targets, Ascendis Pharma's strategic strengths in product development and market expansion present growth opportunities.
The company's focus on innovation, commercial execution, and market positioning underscores its potential to become a leader in growth disorders and metabolic diseases.
Investors should monitor Ascendis Pharma's progress in achieving cash flow breakeven, expanding product portfolios, and navigating regulatory landscapes for future growth potential.

Ascendis Pharma excels in Q2 with YORVIPATH approval and revenue growth

Ascendis Pharma's Q2 2024 earnings call highlighted strong financial performance, successful product approvals, and strategic commercialization efforts.
The company faces challenges in pricing strategies, market dynamics, and ensuring patient uptake, but opportunities exist in expanding market reach and advancing pipeline programs.
Overall, Ascendis Pharma's focus on innovation, patient support, and financial growth positions it well for continued success and market leadership in the biopharmaceutical industry.

Ascendis Pharma reports robust Q3 performance and eyes strategic growth

Ascendis Pharma showcased strong performance across its product portfolio and pipeline candidates, with notable revenue growth and promising clinical outcomes.
While facing challenges in market penetration and regulatory processes, the company is well-positioned to capitalize on growth opportunities through strategic collaborations and upcoming product launches.
By navigating challenges effectively and leveraging opportunities, Ascendis Pharma aims to drive sustainable growth and value creation in the pharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients' lives, today announced that the company will participate in two upcoming investor conferences. Company executives will provide a business overview and update on the company's programs.

Ascendis Pharma A/S Announces Upcoming Investor Presentations

– TransCon IL-2 β/γ  is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation of IL-2Rβ/γ  with low C max –

Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program

Cara Therapeutics

Jazz Pharmaceuticals

Sesen Bio Inc.

Sanofi

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

The pharmaceutical company saw its shares jump more than $26.

Why Shares of Ascendis Soared This Week

Approval of the company's weekly growth hormone is making investors smile today.

Here's Why Ascendis Pharma Shares Are Surging Higher Today

The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ages one and older with growth hormone deficiency (GHD) who weigh at least 25.4 pounds.

See Why Ascendis Pharma Stock Is Shining On Thursday

The stock price of Ascendis Pharma A/S (Nasdaq: ASND) increased by over 20% pre-market. This is why it happened.

ASND Stock: Over 20% Increase Pre-Market Explanation

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q2 2021 Results - Earnings Call Transcript

Williams-Sonoma

Find out where the big winners were late Wednesday.

These 2 Stocks Soared Double Digits After Hours

– Announced U.S. Food and Drug Administration Approval of SKYTROFA ® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –

Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results

- SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Ascendis Pharma (ASND) This Earnings Season?

COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Wednesday, August 25, 2021 at 4:30 p.m. Eastern Time (ET) to review its second quarter 2021 financial results and provide a business update.

Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25

COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidates that address unmet medical needs, today announced that the company will participate in two upcoming investor conferences in August. Company executives will provide a business overview and update on the company's pipeline programs.

Ascendis Pharma A/S Announces Upcoming Investor Presentations in August

Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the treatment of pediatric growth hormone deficiency. Citing a major amendment to the application, the agency has pushed the action goal date by three months to September 25.

Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months

Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency

1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathyroid hormone). 2. PaTHway China Trial is designed to assess the potential of TransCon™ PTH as a hormone replacement therapy, and the aim is to enable patients to have serum calcium (sCa) within the normal range and independence from usual care.

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial

Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 0 2 0 1 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 5 analysts offering 12-month price targets in the last 3 months for Ascendis Pharma evaluate the company at an average price target of $188.2 with a high of $201.00 and a low of $176.00.

What 5 Analyst Ratings Have To Say About Ascendis Pharma

Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2021 Results - Earnings Call Transcript

– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –

Ascendis Pharma A/S Reports First Quarter 2021 Financial Results

COPENHAGEN, Denmark, May 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, May 27, 2021 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2021 financial results and provide a business update.

Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27

– Marks next step to bring the potential first ever hormone replacement therapy for hypoparathyroidism to Japan – – Marks next step to bring the potential first ever hormone replacement therapy for hypoparathyroidism to Japan –

Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan

News for Ascendis Pharma Stock (ASND)